logo
First Australian-built rocket ‘Eris' crashes 14 seconds after liftoff in failed orbital bid: Video

First Australian-built rocket ‘Eris' crashes 14 seconds after liftoff in failed orbital bid: Video

Hindustan Times6 days ago
Australia's first domestically built rocket to attempt reaching orbit crashed just 14 seconds after liftoff on Wednesday. The Eris rocket, developed by Gilmour Space Technologies, was launched on a test flight from a spaceport near Bowen in northern Queensland. The Eris rocket, launched by Gilmour Space Technologies on Wednesday, 30 July 2025, near Bowen, Australia, crashed just seconds after lift-off.(Gilmour Space Technologies)
No injuries were reported following the incident.
Eris was the first Australian-designed and manufactured orbital launch vehicle to lift off from the country, intended to carry small satellites into orbit.
Footage shared online shows the 23-metre rocket clearing the launch tower and hovering briefly before plummeting. Thick smoke and flames erupted as it crashed, with dramatic visuals captured and published by Australian media outlets.
Watch video here
'Space is hard'
CEO Adam Gilmour expressed satisfaction that the rocket successfully lifted off the launchpad. "Space is hard," said Adam Gilmour, CEO of Gilmour Space Technologies. 'SpaceX, Rocket Lab and others needed multiple test flights to reach orbit. We've learned a tremendous amount that will go directly into improving our next vehicle, which is already in production.'
The company described the launch as a 'success' in a Facebook post. A spokesperson noted that all four hybrid engines ignited, achieving 23 seconds of engine burn and 14 seconds of flight on its maiden launch.
Gilmour Space Technologies had previously scheduled launches for May and earlier this month, but both were postponed due to technical issues and adverse weather.
'Getting off the pad and into flight is a huge step forward for any new rocket program. This was the first real test of our rocket systems, our propulsion technology, and our spaceport — and it proved that much of what we've built works,' Gilmour said.
'Of course I would have liked more flight time but happy with this,' he posted on LinkedIn. In February, he remarked that it was 'almost unheard of' for a private space firm to succeed in reaching orbit on its first attempt.
The company had earlier indicated it would deem the mission a success if the rocket simply lifted off. According to their statement, the launch site infrastructure 'remained intact. "
Whitsunday Regional Council Mayor Ry Collins described the launch as a 'huge achievement' despite the vehicle not making it to orbit.
'This is an important first step towards the giant leap of a future commercial space industry right here in our region,' he wrote on Facebook.
Gilmour Space Technologies, which is privately funded, recently secured a AU$5 million (£2.6 million) federal government grant this month to support the development of the Eris rocket. This follows a larger AU$52 million funding agreement with the government in 2023 to further space innovation and commercialisation in Australia.
While Australia has hosted hundreds of suborbital launches, there have only been two successful orbital missions from its territory, according to NASASpaceFlight. The Eris test marked the first attempt at an orbital launch from Australia in over 50 years.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Business Standard

timean hour ago

  • Business Standard

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.

Australian regulator says YouTube, others ‘turning a blind eye' to child abuse material
Australian regulator says YouTube, others ‘turning a blind eye' to child abuse material

Indian Express

time2 hours ago

  • Indian Express

Australian regulator says YouTube, others ‘turning a blind eye' to child abuse material

Australia's online safety regulator has said that major tech companies, including YouTube and Apple, are not doing enough to stop child sexual abuse material from appearing on their platforms. In a report published on Wednesday, the eSafety Commissioner said YouTube had been especially unresponsive to questions and failed to share how many user reports it receives or how long it takes to act on them. The same was said of Apple. 'When left to their own devices, these companies aren't prioritising the protection of children and are seemingly turning a blind eye to crimes occurring on their services,' said Julie Inman Grant, Australia's eSafety Commissioner, in comments reported by Reuters. The Australian government recently decided to include YouTube in its social media restrictions for teenagers, after the regulator advised against giving it an exemption. The report looked at how Apple, Google, Meta, Microsoft, Discord, Skype, Snap, and WhatsApp are addressing child abuse content. According to the findings, many platforms had gaps in safety. These included poor systems for detecting live-streamed abuse, weak methods for reporting harmful content, and a failure to block known child abuse links. The regulator also said some companies had not taken action even after being warned in previous years. It pointed out that not all companies were using 'hash-matching' technology across their services – a tool used to detect known child abuse images by comparing them to a database. 'In the case of Apple services and Google's YouTube, they didn't even answer our questions about how many user reports they received about child sexual abuse on their services or details of how many trust and safety personnel Apple and Google have on staff,' Inman Grant told Reuters. Google has previously said it uses industry-standard tools, including hash-matching and artificial intelligence, to detect and remove abuse material. Meta, which owns Facebook, Instagram and Threads, says it bans graphic content on its platforms.

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

Mint

time2 hours ago

  • Mint

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store